YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Key Points Interested in Ligand Pharmaceuticals Incorporated? Here are five stocks we like better. XOMA acquisition doubled Ligand's portfolio to more than 220 partnered programs, adding seven commercial-stage assets, 14 late-stage program…
WAYNE, Pa., July 28, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare sk…
(RTTNews) - Today's top biotech gainers include Wellgistics following its rebranding, Femasys, which recently resolved its Nasdaq compliance issue, Vor Bio with continued progress in its Telitacicept program, and Sol-Gel Technologies as in…
Palvella Therapeutics Inc. (NASDAQ:PVLA) is one of the 10 affordable biotech stocks to buy right now. On June 29, Palvella Therapeutics Inc. (NASDAQ:PVLA) disclosed that it filed the initial module of its New Drug Application with the FDA…
Palvella Therapeutics Inc. Brings more than 25 years of experience advancing and commercializing high-impact therapies for serious diseases, including those with limited or no approved treatment options Extensive public company and rare di…
FDA’s rolling review process is intended to facilitate expedited review, enabling FDA to begin evaluating completed modules of the NDA before the full application is submitted FDA previously granted Breakthrough Therapy and Fast Track desi…
Key Points 4,302 common shares were exercised and sold on June 17, 2026, for $476,000 at a weighted average price of around $110.73 per share. This was a derivative transaction involving the exercise and immediate sale of options. No indir…
Kathleen Goin, Chief Operating Officer of Palvella Therapeutics (NASDAQ:PVLA), reported the exercise of 4,302 stock options immediately converted and sold as common shares for a transaction value of approximately $476,000 according to the…
(RTTNews) - "The market is a device for transferring money from the impatient to the patient." - Warren Buffett. Successful investing often comes down to patience, conviction, and the ability to stay the course through market fluctuations.…
FDA’s rolling review process is intended to facilitate expedited review, enabling FDA to begin evaluating completed sections of the NDA before the full application is submitted Palvella remains on track to complete the NDA submission in th…
Palvella remains on track to submit an NDA in the second half of 2026 Microcystic lymphatic malformations are serious, chronic, lifelong vascular malformations that can cause persistent leaking, bleeding, infection, functional impairment,…
WAYNE, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients su…
Uplisting reflects Palvella’s continued progress advancing potential first-in-disease therapies for serious, rare skin diseases and vascular malformations WAYNE, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella o…
Palvella Therapeutics Inc. Uplisting reflects Palvella’s continued progress advancing potential first-in-disease therapies for serious, rare skin diseases and vascular malformations WAYNE, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Palvella The…
By John Vandermosten, CFA NASDAQ: LGND READ THE FULL LGND RESEARCH REPORT Ligand Pharmaceuticals, Inc. (NASDAQ: LGND) reported first quarter 2026 results with revenues of $51.7 million and adjusted core earnings per share (EPS) of $1.63. R…
Ligand Pharmaceuticals logo Key Points Interested in Ligand Pharmaceuticals Incorporated? Here are five stocks we like better. Ligand's Q1 was driven by royalties: total revenue was $52 million (+14% YoY) with royalty revenue $43 million (…
Ligand Pharmaceuticals JUPITER, Fla., May 05, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor conferences: H.C.…
We just covered the Billionaire Joe Edelman’s 10 Stock Picks with Huge Upside Potential and Roivant Sciences Ltd. (NASDAQ:ROIV) ranks 8th on this list. Roivant Sciences Ltd. (NASDAQ:ROIV) recently won a major legal battle. In March, Roivan…
We just covered the 14 Best Low Risk High Growth Stocks to Buy Right Now and Eli Lilly and Company (NYSE:LLY) ranks 2nd on this list. Eli Lilly and Company (NYSE:LLY) is often referred to as the leading contender to become the first trilli…
Palvella Therapeutics Inc. Mr. Taylor brings a strong track record launching multiple high-profile therapies, most recently serving as Senior Vice President, Sales at Arcutis Biotherapeutics (Nasdaq: ARQT), where he led U.S. sales efforts…
Review delineates differences in clinical strategies between microcystic and macrocystic lymphatic malformations to guide disease-specific clinical trial design and treatment approaches Manuscript emphasizes the importance of early therape…
Quant rankings for the upcoming earnings calendar show strength concentrated in consumer discretionary and select industrial and health care names, while weakness is more pronounced across health care, technology, and parts of consumer-fac…
Kathleen Goin, the chief operating officer of Palvella Therapeutics, Inc.(NASDAQ:PVLA), executed the exercise of 4,302 options and immediately sold an equivalent number of common shares on March 18, 2026, according to an SEC Form 4 filing.…
Key Points An executive at Palvella Therapeutics reported selling 4,302 common shares for approximately $508,000 on March 18, 2026. The disposal resulted from the immediate sale of shares acquired through option exercise. No indirect holdi…
George M. Jenkins, a director of Palvella Therapeutics(NASDAQ:PVLA), participated in the company's underwritten public offering on Feb. 27, 2026, purchasing 4,000 shares at the offering price of $125.00 per share for a total of approximate…
Palvella Therapeutics Inc. Ms. McDonough previously served as Senior Vice President of Patient Access, Analytics, and Operations at Krystal Biotech (Nasdaq: KRYS), where she helped lead the U.S. launch of VYJUVEK®, supporting its growth fr…
Patent strengthens global intellectual property protection for QTORIN™ rapamycin, Palvella’s lead product candidate from the QTORIN™ platform, in development for serious, rare skin diseases and vascular malformations with no FDA-approved t…
By John Vandermosten, CFA NASDAQ:LGND READ THE FULL LGND RESEARCH REPORT Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) reported 2025 results with revenues of $268 million and adjusted core earnings per share (EPS) of $8.13. Both numbers were…
(RTTNews) - Palvella Therapeutics, Inc. (PVLA) has priced an upsized public offering of 1.6 million shares of common stock at $125.00 per share, with expected gross proceeds of $200 million before underwriting discounts and expenses. Under…
WAYNE, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (“Palvella”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from se…
H.C. Wainwright raised the firm’s price target on Palvella Therapeutics (PVLA) to $255 from $200 and keeps a Buy rating on the shares. Phase 3 SELVA data, with the mLM-IGA primary endpoint demonstrating a statistically significant 2.13-poi…
The S&P 500 Index ($SPX) (SPY) on Tuesday closed up +0.77%, the Dow Jones Industrial Average ($DOWI) (DIA) closed up +0.76%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +1.09%. March E-mini S&P futures (ESH26) rose +0.76%, and March E…
The S&P 500 Index ($SPX) (SPY) on Tuesday closed up +0.77%, the Dow Jones Industrial Average ($DOWI) (DIA) closed up +0.76%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +1.09%. March E-mini S&P futures (ESH26) rose +0.76%, and March E…
The S&P 500 Index ($SPX) (SPY) today is up +0.50%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.75%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.90%. March E-mini S&P futures (ESH26) are up +0.45%, and March E-mini Nasdaq fu…
The S&P 500 Index ($SPX) (SPY) today is up +0.17%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.64%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.47%. March E-mini S&P futures (ESH26) are up +0.20%, and March E-mini Nasdaq fu…
The S&P 500 Index ($SPX) (SPY) today is up +0.50%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.75%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.90%. March E-mini S&P futures (ESH26) are up +0.45%, and March E-mini Nasdaq fu…